Haemodynamically unstable / high-risk PE: HR >110, SBP <100 mmHg, SpO2 <90% on air; peri-arrest or cardiac arrest
Investigations
Wells/Geneva score to guide work-up (stable patients)
D-dimer if low/intermediate probability
CT pulmonary angiography if high probability or positive D-dimer
ECG (sinus tach or S1Q3T3), troponin/BNP if massive PE suspected
Unstable patient: consider bedside echo (TTE) for RV strain โ do not rely on ultrasound to rule in life-threatening PE; confirm with urgent CT pulmonary angiogram (unless in arrest)
Before thrombolysis: check contraindications, baseline INR, aPTT, platelets, weight
Treatment
Stable patients: anticoagulation (LMWH, unfractionated heparin, or DOAC) once confirmed/high suspicion; supportive care with O2 and cautious fluids (avoid overload with RV strain); risk-stratify for outpatient vs admission (e.g. PESI score)
Unstable PE โ consent: obtain consent for alteplase if possible; document risk of bleeding (10โ15%), intracranial bleeding (~2%) and risk of death
Unstable PE โ prepare: check for contraindications (below) and prescribe Alteplase 100mg in 50 mL water for injection; do NOT exceed 1.5 mg/kg in patients under 65 kg
Peri-arrest:Alteplase 10mg IV over 2 minutes, THEN 90mg IV over 2 hours
Cardiac arrest:Alteplase 50mg IV over 2 minutes with ongoing CPR โ continue CPR for 90 minutes after thrombolysis if ROSC is not achieved. (Literature: a second 50mg bolus after 15 min may be considered if no ROSC)
Weight-based regimen (bolus over 1โ2 min, then 2-hour infusion):10mg bolus then โ low bleeding risk: 40kg 50mg; 45kg 55mg; 50kg 60mg; 55kg 70mg; 60kg 80mg; โฅ65kg 90mg. Moderate bleeding risk: 40mg infusion (unlicensed dose, from the PEITHO trial)
Absolute contraindications: haemorrhagic stroke at any time; ischaemic stroke within 4 months; CNS damage or neoplasia; major trauma or surgery within 2 months; head injury within 2 months; genital/urinary tract bleeding within 2 months; INR >1.7; aPTT >40; platelets <100,000; currently on a DOAC; alteplase allergy; aortic dissection. In life-threatening situations these become relative contraindications
Relative contraindications: acute pulmonary disease with cavitation; acute pancreatitis; aneurysmal condition; bacterial endocarditis; oesophageal varices; pericarditis; suspected peptic ulceration; pregnancy or within 4 weeks post-partum; arterial puncture at a non-compressible site within 7 days
Blood pressure monitoring: if no arterial line, BP every 15 min for the first 2h; if satisfactory, every 30 min during hours 2โ6, then hourly for 12h
Heparin after thrombolysis: check aPTT ratio immediately; aim for ratio <2.3 before resuming IV unfractionated heparin maintenance infusion; if >2.3, recheck every 4h until <2.3, then restart. Once running, target aPTT ratio 1.6โ2.3 (literature dosing: UFH 80 units/kg IV bolus then 18 units/kg/h, adjusted per local nomogram). Continue for at least 24h, then once stable change to an oral anticoagulant (warfarin or DOAC) or LMWH as appropriate
Bleeding on alteplase: monitor puncture and catheter sites; avoid rigid catheters, IM injections and non-essential handling. Stop alteplase immediately if dangerous haemorrhage (e.g. cerebral). Clotting factors need not be replaced (short half-life). Most bleeds: interrupt thrombolytic and anticoagulant, volume replacement, manual pressure. If heparin given within 4h of bleed onset, consider Protamine sulphate (literature: 1mg per 100 units of heparin given in the preceding 2โ3h, max 50mg). Blood products if no response โ discuss with the responsible consultant